ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 355,37
1,00%
Dow Jones
42 992,21
-0,77%
DAX
19 984,32
0,74%
Brent Oil
73,44
0,00%
Bitcoin
94 924,06
-0,23%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Mersana Therapeutics Inc (MRSN) Cours

Mersana Therapeutics Inc

Mersana Therapeutics Inc (MRSN)

NASDAQ
1,50
0,08
(5,63%)
Fermé 29 Décembre 10:00PM
Retardé de 15 minutes
1,44
-0,06
(-4,00%)
Après les heures de négociation: 1:39AM
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
1,44
Prix Achat
1,43
Prix Vente
1,50
Volume échangé
1 342 919
1,40 Fourchette du Jour 1,52
1,22 Plage de 52 semaines 6,2801
Cap du marché
177,887M
Clôture Veille
1,42
Ouverture
1,40
Dernière Transaction
550
@
1.44
(formt)
Dernière heure de transaction
Volume financier
US$ 1 934 451
VWAP
1,4405
Volume moyen (3 m)
1 146 429
Actions en circulation
123 532 909
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-1,08
Bénéfice par action (BPA)
-1,39
Chiffre d'affairess
36,86M
Bénéfice net
-171,67M

À propos de Mersana Therapeutics Inc

Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is... Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.mersana.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Mersana Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker MRSN. Le dernier cours de clôture d'Mersana Therapeutics était de US$1,42. Au cours de la dernière année, les actions de Mersana Therapeutics ont été négociées dans une fourchette de prix de US$ 1,22 à US$ 6,2801.

Mersana Therapeutics compte actuellement 123 532 909 actions en circulation. La capitalisation boursière d'Mersana Therapeutics est de US$175,42 million. Mersana Therapeutics a un ratio cours/bénéfice (ratio PE) de -1.08.

MRSN Dernières nouvelles

Plus de nouvelles

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

26 Décembre 2024
Edgar (US Regulatory)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

24 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

19 Décembre 2024
Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

15 Novembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

13 Novembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

13 Novembre 2024
Edgar (US Regulatory)

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET...

13 Novembre 2024
GlobeNewswire Inc.

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...

06 Novembre 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

29 Octobre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.24-14.28571428571.681.681.3816751261.52592097CS
4-0.82-36.28318584072.262.82921.3812805451.97804644CS
12-0.64-30.76923076922.082.831.3811464292.13137022CS
26-0.6-29.41176470592.042.831.2211276031.95120304CS
52-0.73-33.64055299542.176.28011.2215652263.01994648CS
156-4.82-76.99680511186.269.620.801420751853.42220232CS
260-5.31-78.66666666676.7529.090.801416230736.37801809CS

MRSN - Frequently Asked Questions (FAQ)

What is the current Mersana Therapeutics share price?
The current share price of Mersana Therapeutics is US$ 1,44
How many Mersana Therapeutics shares are in issue?
Mersana Therapeutics has 123 532 909 shares in issue
What is the market cap of Mersana Therapeutics?
The market capitalisation of Mersana Therapeutics is USD 175,42M
What is the 1 year trading range for Mersana Therapeutics share price?
Mersana Therapeutics has traded in the range of US$ 1,22 to US$ 6,2801 during the past year
What is the PE ratio of Mersana Therapeutics?
The price to earnings ratio of Mersana Therapeutics is -1,08
What is the cash to sales ratio of Mersana Therapeutics?
The cash to sales ratio of Mersana Therapeutics is 5,03
What is the reporting currency for Mersana Therapeutics?
Mersana Therapeutics reports financial results in USD
What is the latest annual turnover for Mersana Therapeutics?
The latest annual turnover of Mersana Therapeutics is USD 36,86M
What is the latest annual profit for Mersana Therapeutics?
The latest annual profit of Mersana Therapeutics is USD -171,67M
What is the registered address of Mersana Therapeutics?
The registered address for Mersana Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Mersana Therapeutics website address?
The website address for Mersana Therapeutics is www.mersana.com
Which industry sector does Mersana Therapeutics operate in?
Mersana Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
INTZIntrusion Inc
US$ 2,167
(381,56%)
187,57M
AILEiLearningEngines Inc
US$ 0,5932
(267,31%)
557,72M
HUBCWHub Cyber Security Ltd
US$ 0,035
(250,00%)
2,65M
GTIGraphjet Technology
US$ 0,967551
(185,83%)
398,75M
LITMSnow Lake Resources Ltd
US$ 1,61
(82,95%)
129,92M
NEUPNeuphoria Therapeutics Inc
US$ 4,11
(-92,30%)
940,73k
VIRXViracta Therapeutics Inc
US$ 0,16
(-32,49%)
9,47M
PRFXPainReform Ltd
US$ 3,48
(-28,98%)
949,52k
AIREreAlpha Tech Corporation
US$ 2,56
(-28,49%)
8,42M
AVGRAvinger Inc
US$ 0,9721
(-24,05%)
2,16M
AILEiLearningEngines Inc
US$ 0,5932
(267,31%)
557,72M
GTIGraphjet Technology
US$ 0,967551
(185,83%)
398,75M
RGTIRigetti Computing Inc
US$ 17,08
(10,62%)
298,47M
XTIAXTI Aerospace Inc
US$ 0,03935
(-1,63%)
263,01M
QSIQuantum Si Inc
US$ 3,585
(66,74%)
250,36M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
MRSN
Mersana Therapeutics
LSE
0E8M
Monrif
UPBT
API3BTC
API3
COIN
CROUSD
Cronos Coin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés